Anavex Life Sciences Valuation
Is 0HFR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0HFR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0HFR ($9.4) is trading below our estimate of fair value ($636.57)
Significantly Below Fair Value: 0HFR is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0HFR?
Key metric: As 0HFR is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is 0HFR's PB Ratio? | |
|---|---|
| PB Ratio | 5.9x |
| Book | US$129.78m |
| Market Cap | US$766.13m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 0HFR's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.7x | ||
OXB Oxford Biomedica | 6.8x | 93.2% | UK£447.8m |
PRTC PureTech Health | 1.6x | -13.0% | UK£405.6m |
GNS Genus | 2x | 37.7% | UK£1.1b |
BVXP Bioventix | 16.4x | n/a | UK£197.0m |
0HFR Anavex Life Sciences | 5.9x | 47.7% | US$766.1m |
Price-To-Book vs Peers: 0HFR is good value based on its Price-To-Book Ratio (5.9x) compared to the peer average (6.7x).
Price to Book Ratio vs Industry
How does 0HFR's PB Ratio compare vs other companies in the GB Biotechs Industry?
Price-To-Book vs Industry: 0HFR is expensive based on its Price-To-Book Ratio (5.9x) compared to the UK Biotechs industry average (2.8x).
Price to Book Ratio vs Fair Ratio
What is 0HFR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 5.9x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 0HFR's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$9.40 | US$35.47 +277.2% | 33.9% | US$46.00 | US$15.00 | n/a | 4 |
| Nov ’25 | US$6.90 | US$35.47 +414.1% | 33.9% | US$46.00 | US$15.00 | n/a | 4 |
| Oct ’25 | US$5.41 | US$35.47 +555.7% | 33.9% | US$46.00 | US$15.00 | n/a | 4 |
| Sep ’25 | US$5.86 | US$35.47 +505.8% | 33.9% | US$46.00 | US$15.00 | n/a | 4 |
| Aug ’25 | US$6.52 | US$35.47 +444.1% | 33.9% | US$46.00 | US$15.00 | n/a | 4 |
| Jul ’25 | US$4.11 | US$27.50 +569.3% | 45.5% | US$40.00 | US$15.00 | n/a | 2 |
| Jun ’25 | US$4.06 | US$27.50 +577.3% | 45.5% | US$40.00 | US$15.00 | n/a | 2 |
| May ’25 | US$3.60 | US$32.50 +803.3% | 23.1% | US$40.00 | US$25.00 | n/a | 2 |
| Apr ’25 | US$5.06 | US$32.50 +542.3% | 23.1% | US$40.00 | US$25.00 | n/a | 2 |
| Mar ’25 | US$5.33 | US$32.50 +509.8% | 23.1% | US$40.00 | US$25.00 | n/a | 2 |
| Dec ’24 | US$7.46 | US$47.00 +530.0% | 14.9% | US$54.00 | US$40.00 | n/a | 2 |
| Nov ’24 | US$5.53 | US$47.00 +749.9% | 14.9% | US$54.00 | US$40.00 | US$6.90 | 2 |
| Oct ’24 | US$6.56 | US$47.00 +616.6% | 14.9% | US$54.00 | US$40.00 | US$5.41 | 2 |
| Sep ’24 | US$8.01 | US$47.00 +486.6% | 14.9% | US$54.00 | US$40.00 | US$5.86 | 2 |
| Aug ’24 | US$8.12 | US$47.00 +478.9% | 14.9% | US$54.00 | US$40.00 | US$6.52 | 2 |
| Jul ’24 | US$8.14 | US$47.00 +477.3% | 14.9% | US$54.00 | US$40.00 | US$4.11 | 2 |
| Jun ’24 | US$9.24 | US$47.00 +408.6% | 14.9% | US$54.00 | US$40.00 | US$4.06 | 2 |
| May ’24 | US$8.14 | US$47.00 +477.5% | 14.9% | US$54.00 | US$40.00 | US$3.60 | 2 |
| Apr ’24 | US$8.57 | US$40.67 +374.5% | 26.1% | US$54.00 | US$28.00 | US$5.06 | 3 |
| Mar ’24 | US$9.66 | US$39.33 +307.2% | 22.9% | US$50.00 | US$28.00 | US$5.33 | 3 |
| Feb ’24 | US$10.12 | US$41.67 +311.6% | 15.0% | US$50.00 | US$35.00 | US$6.11 | 3 |
| Jan ’24 | US$9.07 | US$32.00 +252.8% | 38.7% | US$42.00 | US$11.00 | US$9.43 | 4 |
| Dec ’23 | US$8.92 | US$33.25 +272.7% | 30.9% | US$42.00 | US$16.00 | US$7.46 | 4 |
| Nov ’23 | US$12.45 | US$33.25 +167.2% | 30.9% | US$42.00 | US$16.00 | US$5.53 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Formycon
€857.2m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
0W4N
€48.65
7D
3.6%
1Y
-24.5%
hVIVO
UK£144.6m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.21
7D
-3.8%
1Y
4.9%
Laboratorios Farmaceuticos Rovi
€3.3b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€64.00
7D
3.6%
1Y
15.7%